Author:
Trevisan B.,Pepe F. F.,Vallini I.,Montagna E.,Amoroso D.,Berardi R.,Butera A.,Cagossi K.,Cavanna L.,Ciccarese M.,Cinieri S.,Cretella E.,De Conciliis E.,Febbraro A.,Ferraù F.,Ferzi A.,Baldelli A.,Fontana A.,Gambaro A. R.,Garrone O.,Gebbia V.,Generali D.,Gianni L.,Giovanardi F.,Grassadonia A.,Leonardi V.,Sarti S.,Musolino A.,Nicolini M.,Putzu C.,Riccardi F.,Santini D.,Sarobba M. G.,Schintu M. G.,Scognamiglio G.,Spadaro P.,Taverniti C.,Toniolo D.,Tralongo P.,Turletti A.,Valenza R.,Valerio M. R.,Vici P.,Clivio L.,Torri V.,Cazzaniga M. E.,
Abstract
AbstractNowadays, treatment of metastatic breast cancer (MBC) has been enriched with novel therapeutical strategies. Metronomic chemotherapy (mCHT) is a continuous and frequent administration of chemotherapy at a lower dose and so whit less toxicity. Thus, this strategy could be attractive for elderly MBC patients. Aim of this analysis is to provide insights into mCHT’s activity in a real-life setting of elderly MBC patients. Data of patients ≥ 75 years old included in VICTOR-6 study were analyzed. VICTOR-6 is a multicentre, Italian, retrospective study, which collected data on mCHT in MBC patients treated between 2011 and 2016. A total of 112 patients were included. At the beginning of mCHT, median age was 81 years (75–98) and in 33% of the patients mCHT was the first line choice. Overall Response Rate (ORR) and Disease Control Rate (DCR) were 27.9% and 79.3%, respectively. Median PFS ranged between 7.6 and 9.1 months, OS between 14.1 and 18.5 months. The most relevant toxicity was the hematological one (24.1%); severe toxicity (grade 3–4) ranged from 0.9% for skin toxicity up to 8% for hematologic one. This is a large study about mCHT in elderly MBC patients, providing insights to be further investigated in this subgroup of frail patients.
Publisher
Springer Science and Business Media LLC